Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by MYSTICALon Oct 06, 2015 9:11pm
240 Views
Post# 24169729

RE:RE:RE:RE:RE:Pretty impressive

RE:RE:RE:RE:RE:Pretty impressiveIts normal that there a drop after a run up. From $1.39 to $1.88. Its always good to take a profit. Need to keep the focus on the long run.... Insider are buying at these levels and that's always a good indications. Lets not forget why we are here. Paradigm Capital reaffirmed a buy rating and issued a C$3.75 price target on shares of ProMetic Life Sciences in a research report on Monday, September 28th. Canaccord Genuity lowered their price objective on ProMetic Life Sciences to C$3.50 and set a buy rating on the stock in a research report on Monday, August 17th. Finally, Scotiabank set a C$3.00 price target on ProMetic Life Sciences and gave the company an outperform rating in a research report on Thursday, July 9th. Five equities research analysts have rated the stock with a buy rating, The company has an average rating of Buy and a consensus target price of C$3.33.
Bullboard Posts